Gallbladder Disease on Ozempic (semaglutide 0.5-2 mg): Incidence, Severity, and Realistic Expectations

What the Ozempic label says about the gallbladder

The Ozempic label lists acute gallbladder disease as a warning: if cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated [1]. Cholecystitis and cholecystectomy, removal of the gallbladder, also appear among the label's postmarketing reports, for which frequency cannot be estimated [1].

Gallbladder disease is not a contraindication to Ozempic. The contraindications listed in the label are a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and a prior serious hypersensitivity reaction to semaglutide or any excipient [1].

Gallstone rates by dose in the label's own trials

In the label's placebo-controlled trials, cholelithiasis was reported in 1.5% of patients treated with 0.5 mg and 0.4% treated with 1 mg, and was not reported in placebo-treated patients [1]. The label gives no corresponding cholelithiasis rate for the 2 mg dose [1].

A separate 40-week trial of 959 adults with type 2 diabetes compared 1 mg with 2 mg and reported no new safety signals [1]. That is a statement about the overall safety profile, not a gallbladder-specific comparison.

The 2.4 mg picture from SELECT

SELECT enrolled 17,604 adults aged 45 and older with established cardiovascular disease and a body-mass index of 27 or more but no diabetes, assigned to semaglutide 2.4 mg weekly or placebo, with a mean follow-up of 39.8 months [3]. Gallbladder-related disorders occurred in 2.8% of the semaglutide group versus 2.3% of the placebo group (p=0.04). The difference came mainly from cholelithiasis, at 1.4% versus 1.1%, while cholecystitis was 0.6% in both groups [2].

What pooled analyses add

Two meta-analyses put the signal in a wider frame. Across 21 randomized trials and 99,599 patients, GLP-1 receptor agonists were associated with a 26% higher rate of gallbladder disorders than control [4]. Restricted to semaglutide in people with overweight or obesity and no diabetes, nine studies with 11,641 participants on semaglutide and 10,479 on placebo gave an odds ratio of 1.26 for gallbladder disorders (p=0.010) and 2.06 for cholelithiasis (p=0.04) [5]. A 2021 review of semaglutide safety reached the same conclusion, that the drug increases the risk of biliary disease, specifically cholelithiasis [6].

One adolescent trial reported a wider gap: among 201 participants aged 12 to under 18 treated for 68 weeks, cholelithiasis occurred in 4% on semaglutide 2.4 mg versus 0% on placebo [7].

Which figures are dose-specific to Ozempic?

The 2.8% and 2.3% figures come from a 2.4 mg weekly trial [2], and the meta-analyses pool different doses and, in one case, eight different medicines, so neither is a dose-specific Ozempic figure [4][5]. Only the label's 1.5% and 0.4% figures are for Ozempic's own 0.5 mg and 1 mg doses [1].

How serious are the recorded events?

The reported events include gallstones and gallbladder inflammation, and SELECT also reported a broader category of gallbladder-related disorders [2]. Cholecystectomy appears in the Ozempic label's postmarketing reports, so some patients treated with the drug had their gallbladder removed [1]. In SELECT, the difference was concentrated in gallstones rather than inflammation, with cholecystitis at 0.6% in both arms [2].

If gallbladder disease is suspected

The label's position is that gallbladder studies are indicated when cholelithiasis or cholecystitis are suspected [1]. The same statement appears in the Rybelsus and Ozempic tablets label [8].

Absolute and relative differences

For semaglutide 2.4 mg in SELECT, the absolute difference was 0.5 percentage points over a mean 39.8 months: 2.8% versus 2.3% [2][3]. The 26% figure from the pooled analysis is a relative difference rather than an absolute one, and it applies to the GLP-1 class as a whole rather than to any single dose of Ozempic [4]. These numbers describe how often a gallbladder diagnosis or event was recorded in a trial population, not how severe any individual case was.